ROIV ROIVANT SCIENCES LTD

Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP.

Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call.

Webcast Details

The company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. Please click to register for the event. The live webcast will also be available under “Events & Presentations” in the Investors section of the Roivant website at /news-events/events. The archived webcast will be available on Roivant’s website after the conference call.

About Roivant

Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. For more information,

Contacts:

Investors

Keyur Parekh

Media

Stephanie Lee



EN
18/03/2025

Underlying

ROIVROIVANT SCIENCES LTD

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ROIVANT SCIENCES LTD

 PRESS RELEASE
Free
ROIV ROIVANT SCIENCE...

Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Bil...

Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appealIf the $1.3 billion payment is realized, this settlement will be the largest disclosed patent settlement paid in the pharmaceutical industry and the second largest in any industrySettlement holds Moderna accountable for infringement and provides for the court to enter judgment of no invalidity on the four Genevant/Arbutus patents ...

March 3, 2026 1 EN
 PRESS RELEASE
Free
ROIV ROIVANT SCIENCE...

Priovant Announces FDA Acceptance and Priority Review of New Drug Appl...

Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis FDA assigns PDUFA target action date in the third quarter of calendar year 2026 with launch expected at the end of September 2026Priority Review supported by positive Phase 3 VALOR results, the first positive 52-week placebo-controlled trial in dermatomyositisIf approved, brepocitinib would represent the first targeted therapy approved for dermatomyositis DURHAM, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics today announced that the U.S. Food and Drug Admin...

March 3, 2026 1 EN
 PRESS RELEASE
Free
ROIV ROIVANT SCIENCE...

Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutane...

Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ 21.6 P

February 6, 2026 1 EN
 PRESS RELEASE
Free
ROIV ROIVANT SCIENCE...

Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneo...

Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025 Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ21.6 P

February 6, 2026 1 EN
 PRESS RELEASE
Free
ROIV ROIVANT SCIENCE...

Roivant to Report Financial Results for the Third Quarter Ended Decemb...

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 BASEL, Switzerland and LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 6, 2026, to report its financial results for the second quarter ended December 31, 2026, and provide a business update. To access the conference call by phone, please register online using this . The presentation and webcast details will also be ava...

January 23, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch